Retatrutide 20mg
Retatrutide is a novel triple agonist peptide targeting GIP, GLP-1, and glucagon receptors. Research indicates significant metabolic activity in preclinical and clinical studies. 20mg vial, ≥99% purity, lyophilized powder.
All products currently listed on this site are for research purposes ONLY. All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion. Not for human or animal consumption.
Frequently Bought Together
Retatrutide is a novel triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. This investigational compound has generated significant attention in metabolic research due to its unique tri-receptor mechanism. Each vial contains 20mg of lyophilized peptide at 99%+ purity.